Zura Bio (NASDAQ:ZURA) Trading Down 1.6% – Here’s Why

Zura Bio Limited (NASDAQ:ZURA)’s share price was down 1.6% during trading on Friday . The stock traded as low as $1.22 and last traded at $1.26. Approximately 142,746 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 391,106 shares. The stock had previously closed at $1.28.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZURA. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Chardan Capital decreased their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.80.

Zura Bio Trading Down 1.6 %

The stock’s fifty day moving average price is $1.76 and its 200-day moving average price is $3.01.

Institutional Trading of Zura Bio

Several large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in shares of Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after buying an additional 7,828 shares in the last quarter. Wells Fargo & Company MN grew its stake in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after acquiring an additional 9,379 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. Rhumbline Advisers lifted its position in shares of Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after purchasing an additional 10,231 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in shares of Zura Bio during the fourth quarter worth approximately $27,000. 61.14% of the stock is owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.